How Pragmatic Can Post-Approval Safety Trials Be?
This article was originally published in RPM Report
The February 23 meeting of the Pulmonary Allergy Drugs Advisory Committee included an interesting colloquy on the potential use of pragmatic trials to answer real-world use and safety questions. FDA Division of Pulmonary, Allergy and Rheumatology Director Badrul Chowdhury began the discussion by questioning a reference to “pragmatic trials” by the Chari of the committee, Jerry Krishnan (University of Illinois Hospital & Health Sciences System).
You may also be interested in...
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
COVID treatments have not advanced as rapidly or as publicly as vaccines. That may trigger some issues for the US FDA as Congress digs into the next phase of the COVID response – and starts to assess agency performance and leadership after the crisis.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.